Past two years Past Year Past 30 Days
Abstract Views 1 1 1
Full Text Views 371 104 1
PDF Downloads 53 38 2
 
 
 
 
 
 
 
 
 
 
 

In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance.

H NoedlDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by H Noedl in
Current site
Google Scholar
PubMed
Close
,
W H WernsdorferDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by W H Wernsdorfer in
Current site
Google Scholar
PubMed
Close
,
S KrudsoodDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by S Krudsood in
Current site
Google Scholar
PubMed
Close
,
P WilairatanaDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by P Wilairatana in
Current site
Google Scholar
PubMed
Close
,
P ViriyavejakulDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by P Viriyavejakul in
Current site
Google Scholar
PubMed
Close
,
H KollaritschDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by H Kollaritsch in
Current site
Google Scholar
PubMed
Close
,
G WiedermannDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by G Wiedermann in
Current site
Google Scholar
PubMed
Close
, and
S LooareesuwanDepartment of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Austria.

Search for other papers by S Looareesuwan in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

Cross-resistance may be considered one of the most important factors leading to decreased drug susceptibility of Plasmodium falciparum. The study aimed to determine whether clinically relevant cross-sensitivity of P. falciparum existed between artemisinin and mefloquine. Seventy-six patients with falciparum malaria were admitted and treated with artemisinin derivatives. Treatment response parameters were assessed and in vitro drug sensitivity tests were performed with artemisinin, mefloquine, quinine, and chloroquine. Distinct in vitro cross-sensitivity between artemisinin and mefloquine was observed (p = 0.604; P < 0.001). To assess the relevance of this finding for clinical cross-resistance, we used an analytical model based on the relation of in vivo treatment response parameters (fever, parasite and symptom clearance) to a single reference drug with in vitro drug sensitivity data of several other drugs. Artemisinin (R = 0.554; P = 0.009) and mefloquine (R = 0.615; P = 0.002) in vitro drug sensitivities were equally well reflected in the in vivo treatment response to artemisinin, thereby suggesting the clinical relevance of in vitro cross-sensitivity.

Save